Takeda Ventures, Inc.
Cambridge, Massachusetts, United StatesFounded 2001
Takeda Ventures, Inc. (TVI) is the corporate venture capital arm of Takeda Pharmaceutical Company Limited, founded in 2001. It invests in and nurtures innovative life science companies to create strategic growth opportunities aligned with Takeda's R&D focus areas including oncology, rare genetics, neuroscience, and gastrointestinal and inflammation.
34% of their portfolio is in Biotech & Life Sciences. Deal activity increased 100% year-over-year (2 deals in the last 12 months). Average disclosed round size is $62.4M (across 58 rounds with reported amounts).
Portfolio
55
Fund Size
—
Top Stage
Series A
Last 12 Mo
2
Team
KH
Karen Hong
Senior Investment Director
MG
Miles Gerson
Global Head and President
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
76 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Accipiter Biosciences | Seed | $12.7M | Nov 2025 |
 INTEGRA THERAPEUTICS | Pre-Seed | — | Sep 2025 |
 Oshi Health | Series C | $60M | Jan 2025 |
 Accipiter | Seed | $12.7M | Jan 2025 |
 Seres Therapeutics | Series E | $113M | Jan 2024 |
 OncoResponse | Series D | $13M | May 2023 |
 Ensoma | Series B | $135M | May 2023 |
| Oshi Health | Series B | $30M | Apr 2023 |
 hC Bioscience | Series A | $16M | Nov 2022 |
 Enzyre | Series A | — | Nov 2022 |
 Koneksa Health | Series C | $45M | Feb 2022 |
| KKoneksa | Series C | $4M | Feb 2022 |
| KKoneksa | Series B | $16M | Jan 2022 |
| IIntegra Therapeutics | Seed | — | Dec 2021 |
 AptiHealth | Series B | $50M | Nov 2021 |
 Tele911 | Seed | — | Nov 2021 |
 Egle Therapeutics | Series A | — | Oct 2021 |
 Turnstone Biologics | Series D | $80M | Jul 2021 |
| RRibon | Series B | $65M | Jul 2021 |
 BridGene | Series A | $12M | May 2021 |
 Stride Bio | Series B | $81.5M | Mar 2021 |
| SStrideBio | Series B | $81.5M | Mar 2021 |
| Ensoma | Seed | — | Feb 2021 |
 Aspen RxHealth | Series B | $23M | Jan 2021 |
| AArcellx, Inc. | Series C | $115M | Jan 2021 |
Page 1 of 4
Top Co-Investors
Alexandria Venture Investments13 shared
Sofinnova Partners10 shared
Cormorant Asset Management8 shared
Novartis Venture Fund7 shared
F-Prime Capital6 shared
AbbVie6 shared
Bristol Myers Squibb6 shared
Atlas Venture5 shared
SV Health Investors5 shared
Matrix Partners5 shared
Surveyor Capital5 shared
Forbion5 shared
Foresite Capital5 shared
GV5 shared
Pappas Capital4 shared
OrbiMed4 shared
AdBio partners4 shared
Columbus Venture Partners4 shared
Viking Global Investors4 shared
Last updated: 27 September 2026